AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28399219 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention targeting identified risk factors including physiotherapy, occupational therapy, geriatric assessment, optometry, and medication management
Number of subjects: 221
Study 28399219 — intervention group
Group type: COMPARATOR
Intervention: Individualised written fall prevention advice (Control)
Number of subjects: 221
Study 25861621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 44
Study 23327199 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (Tα1)
Number of subjects: 361
Study 23327199 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 361
Study 21382511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 129
Study 21382511 — intervention group
Group type: COMPARATOR
Intervention: USDA's MyPyramid diet for Pregnancy and Breastfeeding (control diet)
Number of subjects: 129
Study 18435777 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Manual 1:1 structured education
Number of subjects: 245
Study 18435777 — intervention group
Group type: COMPARATOR
Intervention: Control group (6-month delayed-intervention)
Number of subjects: 245
Study 16420539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound reflex transmission imaging (RTI)
Number of subjects: 24
Study 16420539 — intervention group
Group type: EXPERIMENTAL
Intervention: White light (WL) digital photography
Number of subjects: 24
Study 16420539 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of quantitative parameters from RTI and WL photography
Number of subjects: 24
Study 16420539 — intervention group
Group type: EXPERIMENTAL
Intervention: RTI and WL imaging combined
Number of subjects: 24
Study 12766756 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenolutin measured at baseline and at 1 month
Number of subjects: 263
Study 12766756 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenolutin levels at 1 month
Number of subjects: 263
Study 12766756 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline adrenolutin levels
Number of subjects: 263
Study 12766756 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenolutin levels 1 month after random assignment
Number of subjects: 263
Study 12766756 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 263
Study 12766756 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Heart Association class
Number of subjects: 263
Study 11049912 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 60
Study 11049912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 60
Study 11049912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9059951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg p.o. acute; chronic therapy for 2 months)
Number of subjects: 28
Study 9059951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg p.o. chronic therapy for 2 months)
Number of subjects: 28
Study 9059951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8368985 — intervention group
Group type: EXPERIMENTAL
Intervention: Benadryl (diphenhydramine), 50 mg
Number of subjects: 28
Study 8368985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hismanal (astemizole), 10 mg
Number of subjects: 28
Study 8368985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3126122 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth-hormone releasing hormone (GHRH)
Number of subjects: 15
Study 3126122 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 15
Study 3126122 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 15
Study 30016450 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced family/peer support (n=72)
Number of subjects: 218
Study 30016450 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrition education (n=73)
Number of subjects: 218
Study 30016450 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=73)
Number of subjects: 218
Study 27834411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with oxalic acid followed by the application of a two‐step etch‐and‐rinse adhesive system
Number of subjects: 20
Study 27834411 — intervention group
Group type: COMPARATOR
Intervention: Two‐step etch‐and‐rinse adhesive technique (control)
Number of subjects: 20
Study 25556881 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysorb(®) short-term absorbable sutures
Number of subjects: 55
Study 25556881 — intervention group
Group type: COMPARATOR
Intervention: PDS(®)II long-term absorbable sutures
Number of subjects: 55
Study 23949898 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg once daily
Number of subjects: 455
Study 23949898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 21666445 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 200
Study 21666445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18582395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) 300 mg/day
Number of subjects: 128
Study 16649882 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Control Therapy (PCT)
Number of subjects: 80
Study 16649882 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 80
Study 14528786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group from nine CME programs (Perinatology, Pain Management, Fertility Care 2, Pediatrics, Colorectal Diseases, Alzheimer's Disease)
Number of subjects: 667
Study 14528786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention group from nine CME programs
Number of subjects: 667
Study 14528786 — intervention group
Group type: COMPARATOR
Intervention: Control group from nine CME programs
Number of subjects: 667
Study 10780139 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer with organic disease
Number of subjects: 363
Study 10780139 — intervention group
Group type: COMPARATOR
Intervention: Peer without organic disease
Number of subjects: 363
Study 10780139 — intervention group
Group type: EXPERIMENTAL
Intervention: Same sex peer
Number of subjects: 363
Study 10780139 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer with stress
Number of subjects: 363
Study 10780139 — intervention group
Group type: COMPARATOR
Intervention: Peer without stress
Number of subjects: 363
Study 8622596 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 12:0 + 14:0
Number of subjects: 18
Study 8622596 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 16:0 + 18:0
Number of subjects: 18
Study 8622596 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 14:0 + 16:0
Number of subjects: 18
Study 8622596 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental diets
Number of subjects: 18
Study 1315645 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human atrial natriuretic factor (3 pmol min‐1 kg‐1) co-infused with arginine vasopressin
Number of subjects: 9
Study 1315645 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin infusion (0.1 m‐units min‐1 kg‐1)
Number of subjects: 9
Study 1315645 — intervention group
Group type: COMPARATOR
Intervention: Placebo co-infused with arginine vasopressin
Number of subjects: 9
Study 29426574 — intervention group
Group type: COMPARATOR
Intervention: Orthosis alone
Number of subjects: 41
Study 29426574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of orthosis, nerve/tendon gliding exercises, and ultrasound therapy
Number of subjects: 41
Study 30002307 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Photo Appreciation (PPA) program
Number of subjects: 55
Study 30002307 — intervention group
Group type: COMPARATOR
Intervention: Photo Correspondence Education (PCE)
Number of subjects: 55
Study 26381392 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized abutments
Number of subjects: 20
Study 26381392 — intervention group
Group type: COMPARATOR
Intervention: Standard abutments
Number of subjects: 20
Study 25115166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive motivational interviewing (IMI)
Number of subjects: 217
Study 25115166 — intervention group
Group type: COMPARATOR
Intervention: Single standard session of motivational interviewing (SMI) combined with eight nutrition education sessions
Number of subjects: 217
Study 22466469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg)
Number of subjects: 37
Study 22466469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab plus photodynamic therapy (PDT)
Number of subjects: 37
Study 22466469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg) plus PDT
Number of subjects: 37
Study 21256402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensodyne® Pronamel® mouthrinse (450 ppm fluoride)
Number of subjects: 16
Study 21256402 — intervention group
Group type: COMPARATOR
Intervention: Colgate® Fluorigard® (225 ppm fluoride)
Number of subjects: 16
Study 21256402 — intervention group
Group type: COMPARATOR
Intervention: Listerine® Total Care (100 ppm fluoride)
Number of subjects: 16
Study 21256402 — intervention group
Group type: COMPARATOR
Intervention: Listerine Softmint Sensation (0 ppm fluoride)
Number of subjects: 16
Study 17852431 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cholecystectomy (group A)
Number of subjects: 40
Study 17852431 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (group B)
Number of subjects: 40
Study 16100449 — intervention group
Group type: EXPERIMENTAL
Intervention: Newfactan
Number of subjects: 492
Study 16100449 — intervention group
Group type: COMPARATOR
Intervention: Surfacten
Number of subjects: 492
Study 12103383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac microaxial pump (ICP)
Number of subjects: 199
Study 12103383 — intervention group
Group type: COMPARATOR
Intervention: Normothermic cardiopulmonary bypass (CPB)
Number of subjects: 199
Study 10411426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine therapy
Number of subjects: 0
Study 10411426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8983763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordaphene (30 mg)
Number of subjects: 0
Study 8983763 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazeme (180 mg)
Number of subjects: 0
Study 8983763 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (CAs)
Number of subjects: 0
Study 2153475 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 10 ng/kg/min
Number of subjects: 12
Study 2153475 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 30 ng/kg/min
Number of subjects: 12
Study 2153475 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride (10 mg/kg bolus followed by 2 mg/kg/hr infusion)
Number of subjects: 12
Study 2153475 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine with Calcium
Number of subjects: 12
Study 7225741 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CMF)
Number of subjects: 52
Study 7225741 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 52
Study 7225741 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by chemotherapy
Number of subjects: 52
Study 30076173 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin 3 mg/m2 on days 1, 4, and 7 during induction and 3 mg/m2/day on day 1 during consolidation
Number of subjects: 271
Study 30076173 — intervention group
Group type: COMPARATOR
Intervention: Conventional front-line induction chemotherapy (3+7 daunorubicin+cytarabine)
Number of subjects: 271
Study 30076173 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Number of subjects: 271
Study 30076173 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no gemtuzumab ozogamicin)
Number of subjects: 271
Study 28628374 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplement (GeriLact; n = 25)
Number of subjects: 50
Study 28628374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 50
Study 26402448 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-9701
Number of subjects: 40
Study 26402448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23421963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/day
Number of subjects: 0
Study 23421963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/day
Number of subjects: 0
Study 23421963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 120 mg/day
Number of subjects: 0
Study 23421963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23421963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (all doses)
Number of subjects: 0
Study 23421963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study 21351532 — intervention group
Group type: EXPERIMENTAL
Intervention: 32P application device (AD)
Number of subjects: 107
Study 21351532 — intervention group
Group type: COMPARATOR
Intervention: Microwave therapy
Number of subjects: 107
Study 19761700 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole plus levocetirizine
Number of subjects: 132
Study 19761700 — intervention group
Group type: COMPARATOR
Intervention: levocetirizine alone (control group)
Number of subjects: 132
Study 17174639 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (50 mg) and dipyridamole (400 mg)
Number of subjects: 149
Study 17174639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 17174639 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (50 mg) and dipyridamole / Placebo
Number of subjects: 149
Study 16356804 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day (intensive lipid lowering)
Number of subjects: 502
Study 16356804 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day (moderate lipid lowering)
Number of subjects: 502
Study 12105162 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg allopurinol daily for 1 month
Number of subjects: 11
Study 12105162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10337432 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine 0.05% ophthalmic solution
Number of subjects: 36
Study 10337432 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 0.5% ophthalmic solution
Number of subjects: 36
Study 2108712 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin
Number of subjects: 136
Study 2108712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 136
Study 2108712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 390811 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG adjuvant immunotherapy
Number of subjects: 92
Study 390811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BCG treatment)
Number of subjects: 92
Study 30968431 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post‐tetanic count 1‐2) with high doses of rocuronium and 4 mg/kg of sugammadex
Number of subjects: 102
Study 30968431 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train‐of‐four 1‐2) with moderate doses of rocuronium and 2 mg/kg of sugammadex
Number of subjects: 102
Study 30968431 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train‐of‐four 1‐2)
Number of subjects: 102
Study 30968431 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post‐tetanic count 1‐2)
Number of subjects: 102
Study 29023563 — intervention group
Group type: EXPERIMENTAL
Intervention: Venex regeneration wear
Number of subjects: 13
Study 29023563 — intervention group
Group type: COMPARATOR
Intervention: Placebo product
Number of subjects: 13
Study 25575334 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related self-affirming implementation intention (WS-AII)
Number of subjects: 66
Study 25575334 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study 23736997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (1-3 years)
Number of subjects: 535
Study 23736997 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy (Control)
Number of subjects: 535
Study 21368682 — intervention group
Group type: EXPERIMENTAL
Intervention: HAF condition (randomized to receive HAF)
Number of subjects: 6939
Study 21368682 — intervention group
Group type: COMPARATOR
Intervention: No HAF condition (randomized to not receive HAF)
Number of subjects: 6939
Study 19002087 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human activated protein C (rh‐APC)
Number of subjects: 90
Study 19002087 — intervention group
Group type: COMPARATOR
Intervention: Tight glycemic control (TGC)
Number of subjects: 90
Study 16765961 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous technique
Number of subjects: 13
Study 16765961 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional approach)
Number of subjects: 13
Study 16765961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study 14609312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (5 g of glycine, glutamine, and niacin, twice daily for 3 weeks)
Number of subjects: 42
Study 14609312 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 3 weeks)
Number of subjects: 42
Study 11098502 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mitomycin and 5‐FU followed by oral UFT
Number of subjects: 0
Study 11098502 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control)
Number of subjects: 0
Study 8725605 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0
Study 8725605 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy-cholecystectomy
Number of subjects: 0
Study 8725605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 1423566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 1423566 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 3974116 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermodilution cardiac output measurements at peak-inspiration
Number of subjects: 32
Study 3974116 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermodilution cardiac output measurements at end-exhalation
Number of subjects: 32
Study 3974116 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution cardiac output measurements at random times in the respiratory cycle
Number of subjects: 32
Study 30661022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led advance care planning session (1.5 hours)
Number of subjects: 165
Study 30661022 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study 28836456 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5Dindex score at 3 months follow-up
Number of subjects: 132
Study 28836456 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5Dindex score at 12 months follow-up
Number of subjects: 132
Study 28836456 — intervention group
Group type: EXPERIMENTAL
Intervention: External responsiveness analysis using PRWE-Swe
Number of subjects: 132
Study 28836456 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification accuracy of EQ-5Dindex change scores
Number of subjects: 132
Study 28836456 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis with Spearman's ρ test
Number of subjects: 132
Study 25990379 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 30
Study 24741361 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 days of bed rest (BR)
Number of subjects: 7
Study 24741361 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days of normal daily activity after 21 days of bed rest
Number of subjects: 7
Study 22512878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamine (0.5 g/kg/die for 7 days)
Number of subjects: 45
Study 22512878 — intervention group
Group type: COMPARATOR
Intervention: Normal amino acid solution (same quantity for 7 days)
Number of subjects: 45
Study 19879725 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-mm zirconia heads
Number of subjects: 102
Study 19879725 — intervention group
Group type: COMPARATOR
Intervention: 26-mm cobalt-chromium heads
Number of subjects: 102
Study 17943348 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 121
Study 17943348 — intervention group
Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 121
Study 16105865 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Albumin Concentration (UAC)
Number of subjects: 278
Study 16105865 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Albumin-to-Creatinine Ratio (UACR)
Number of subjects: 278
Study 16105865 — intervention group
Group type: EXPERIMENTAL
Intervention: Micral-Test II
Number of subjects: 278
Study 16105865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of diagnosing microalbuminuria
Number of subjects: 278
Study 12356219 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupirocin
Number of subjects: 62
Study 12356219 — intervention group
Group type: COMPARATOR
Intervention: Topical terbinafine
Number of subjects: 62
Study 10690158 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran biscuits (6 per day)
Number of subjects: 19
Study 9095813 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-air loss (LAL) therapy
Number of subjects: 36
Study 9095813 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 1743336 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination using processed fresh semen (Group A)
Number of subjects: 150
Study 1743336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination using the best available cryopreserved semen samples pooled with fresh samples (Group B)
Number of subjects: 150
Study 6352654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (0.5 g every 12 h)
Number of subjects: 62